Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 36

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)

Shi, Alan, Nguyen, Harold, Kuo, C. Benson, Beringer, Paul M. · 2024 · Journal of Cystic Fibrosis

Abstract

INTRODUCTION The efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) have been established in prospective clinical trials. Liver function test elevations were observed in a greater proportion of patients receiving ETI compared with placebo; however, the relatively small number of patients and short duration of study preclude detection of rare but clinically significant associations with drug-induced liver injury (DILI). To address this gap, we assessed the real-world risk of DILI associated with ETI through data mining of the FDA adverse event reporting system (FAERS). METHODS Disproportionality analyses were conducted on FAERS data from the fourth quarter of 2019 through the third quarter of 2022. Comparative patient demographics, onset time and outcomes for ETI-DILI were also obtained. RESULTS 452 reports of DILI associated with ETI were found, representing 2.1 % of all adverse event reports for ETI. All disproportionality measures were significant for ETI-DILI at p < 0.05; the reporting odds ratio (ROR) (2.82) was comparable to that of drugs classified by FDA as "Most-DILI concern". The most notable demographic finding was a male majority (5:4 male to female ratio) for ETI-DILI compared to a female majority (4:5 male to female ratio) for non ETI-DILI. Median ETI-DILI onset time was 50.5 days, and hospitalization was the second most common complication. CONCLUSION Using FAERS data, ETI was found to be disproportionately associated with DILI. Future research is needed to investigate the hepatotoxic mechanisms and assess potential mitigation strategies for ETI-induced hepatotoxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcf.2024.01.001

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 23

  1. Sutharsan, 2022, Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial, Lancet Respir Med, 10, 267, 10.1016/S2213-2600(21)00454-9 · DOI
  2. Barry, 2021, Triple therapy for Cystic Fibrosis, N Engl J Med, 385, 815, 10.1056/NEJMoa2100665 · DOI · Paper page
  3. Zemanick, 2021, A phase 3 open-label study of Elexacaftor/Tezacaftor/Ivacaftor in children 6 through 11 years of age with Cystic Fibrosis and at least one, Am J Respir Crit Care Med, 203, 1522, 10.1164/rccm.202102-0509OC · DOI · Paper page
  4. Mall, 2022, Efficacy and safety of Elexacaftor/Tezacaftor/Ivacaftor in children 6 through 11 years of age with Cystic Fibrosis Heterozygous for, Am J Respir Crit Care Med, 206, 1361, 10.1164/rccm.202202-0392OC · DOI
  5. Tewkesbury, 2023, Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre, J Cyst Fibros, 22, 256, 10.1016/j.jcf.2023.01.007 · DOI
  6. Lowry, 2022, Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor, J Cyst Fibros, 21, e99, 10.1016/j.jcf.2021.07.001 · doi:10.1016/j.jcf.2021.07.001
  7. Bocci, 2022, State of the Art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references, AAPS J, 24, 37, 10.1208/s12248-022-00687-0 · DOI
  8. Chan, 2017, Evaluation of DILI predictive hypotheses in early drug development, Chem Res Toxicol, 30, 1017, 10.1021/acs.chemrestox.7b00025 · DOI
  9. Salehi, 2021, Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio), Respir Med Case Rep, 34
  10. Smith, 2022, Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis, J Cyst Fibros, 21, e8, 10.1016/j.jcf.2021.05.008 · doi:10.1016/j.jcf.2021.05.008
  11. Berthold MR, Cebron N, Dill F, Gabriel TR, Kötter T, Meinl T, et al., editors. KNIME: The konstanz information miner2008; Berlin, Heidelberg: Springer Berlin Heidelberg. · DOI · Paper page
  12. Khaleel, 2022, A standardized dataset of a spontaneous adverse event reporting system, Healthcare (Basel), 10
  13. Zhou, 2022, Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database, Front Pharmacol, 13, 10.3389/fphar.2022.1044744 · DOI
  14. Raschi, 2022, Liver Injury with Nintedanib: a Pharmacovigilance-pharmacokinetic appraisal, Pharmaceuticals (Basel)., 15, 10.3390/ph15050645 · DOI
  15. Evans, 2001, Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports, Pharmacoepidemiol Drug Saf, 10, 483, 10.1002/pds.677 · DOI · Paper page
  16. Amacher, 2014, Female gender as a susceptibility factor for drug-induced liver injury, Hum Exp Toxicol, 33, 928, 10.1177/0960327113512860 · DOI
  17. Rana, 2021, Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury, Acta Pharm Sin B, 11, 3857, 10.1016/j.apsb.2021.05.028 · DOI
  18. McEuen, 2017, Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury, Int J Mol Sci, 18, 10.3390/ijms18071335 · DOI · Paper page
  19. Pannu, 2023, Adverse events of SARS-CoV-2 therapy: a pharmacovigilance study of the FAERS database, Ann Pharmacother
  20. Lu, 2020, Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system, Int J Clin Pharm, 42, 1364, 10.1007/s11096-020-01037-w · doi:10.1007/s11096-020-01037-w
  21. Mazanetz, 2020, Ligand- and structure-based drug design and optimization using KNIME, Curr Med Chem, 27, 6458, 10.2174/0929867326666190409141016 · DOI
  22. Dadi, 2017, SLIMM: species level identification of microorganisms from metagenomes, PeerJ, 5, e3138, 10.7717/peerj.3138 · DOI
  23. Hong, 2023, Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series, Pharmacotherapy, 43, 291, 10.1002/phar.2786 · DOI

Metadata

Authors
Shi, A., Nguyen, H., Kuo, C. B., & Beringer, P. M.
Venue
Journal of Cystic Fibrosis
Publisher
Elsevier BV
Published
2024-05
Volume
23
Issue
3
Pages
566-572
ISSN
1569-1993
Cited by
36
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.